Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are predicting strong performance driven by the robust sales of Lilly's blockbuster medications, particularly the diabetes franchise. However, there are also concerns about potent